Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arcellx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACLX
Nasdaq
8731
https://www.arcellx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arcellx Inc
Insiders Are Dumping These 10 Healthcare Stocks
- Mar 28th, 2024 12:13 pm
Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
- Mar 27th, 2024 5:50 am
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Mar 20th, 2024 8:00 pm
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates
- Mar 2nd, 2024 12:29 pm
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
- Feb 29th, 2024 9:00 pm
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
- Feb 29th, 2024 12:30 am
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
- Feb 28th, 2024 9:00 pm
The 3 Biotech Stocks That Could Make Your February Unforgettable
- Feb 15th, 2024 4:57 pm
Arcellx, Inc. (NASDAQ:ACLX) Shares Could Be 40% Below Their Intrinsic Value Estimate
- Feb 1st, 2024 12:52 pm
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
- Jan 16th, 2024 6:51 pm
Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc
- Dec 22nd, 2023 6:30 am
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
- Dec 15th, 2023 10:04 pm
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
- Dec 8th, 2023 9:00 pm
3 Biotech Stocks That Could Be Multibaggers in the Making
- Dec 1st, 2023 2:37 am
These Stocks Are Exploding In The November Stock Market Rally
- Nov 21st, 2023 1:00 pm
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
- Nov 17th, 2023 11:00 am
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
- Nov 16th, 2023 3:30 pm
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
- Nov 16th, 2023 3:10 pm
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
- Nov 15th, 2023 9:05 pm
Gilead expands Arcellx cancer cell therapy deal
- Nov 15th, 2023 12:16 pm
Scroll